Compare Icl Group Ltd (ICL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Repligen Corporation Common Stock — how do they compare? Icl Group Ltd trades at $4.99 (market cap $6.47B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Icl Group Ltd pays a 4.12% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Repligen Corporation Common Stock for 0 Days on average.
| ICL | RGEN | |
|---|---|---|
Market Cap | $6.47B | $11.31B |
Volume | 1,473,067 | 1,216,919 |
Sector | Basic Materials | Health |
52-Week High | $6.80 | $194.57 |
52-Week Low | $4.80 | $102.87 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $9.10B | $11.20B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $4.98, up 0.81% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating expectations, but revenue and net income have declined from 2022 peaks. Valuation ratios appear reasonable with P/E of 20.75 and P/B of 1.05. All four covering analysts maintain Hold ratings with a $6.08 consensus target, suggesting 22% upside potential.
The outlook remains cautious due to industry headwinds and declining profitability, though the dividend yield provides some support. Key risks include fertilizer market volatility and execution of the cost-transformation program. The stock offers value but requires monitoring of operational improvements and market conditions for sustained recovery.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
